OCGNHealthcare · BiotechnologyThe 6 Wall Street analysts covering Ocugen, Inc. hold a median 12-month price target of $11 — +1252.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Ocugen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OCGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1252.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.50 |
| 27 May 2026 | Canaccord Genuity | Maintains | Buy | $12 → $11 |
| 27 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Mar 2026 | Canaccord Genuity | Initiates | Buy | — |
| 11 Mar 2026 | Oppenheimer | Initiates | Outperform | — |
| 5 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Sept 2025 | Chardan Capital | Maintains | Buy | — |
| 4 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2025 | Chardan Capital | Maintains | Buy | — |
| 12 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OCGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Ocugen, Inc. returned −48.9% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 5% of US stocks
Cheaper than 98% of US stocks
Cheaper than 78% of US stocks
Higher than 49% of US stocks
Higher than 46% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ocugen, Inc. has a market value of $256.7M and an enterprise value of $244.8M.
Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter grew 8.4% year on year.
Net income over the same four quarters: −$81.8M, a −1786.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.25.
Free cash flow in the twelve months to 30 June 2026: −$61.0M.
Trailing P/E: −3.3×; forward P/E: −3.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ocugen, Inc. employs 116 people — $39K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ocugen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ocugen announced it will present its modifier gene therapy platform at investor and industry conferences in November 2026.
Why it matters — OCGN watchers may note the company’s upcoming conference presentations about its gene therapy platform.
Ocugen will host a conference call and live webcast on November 4, 2026, at 8:30 a.m. ET, to provide a business update and report third-quarter 2026 financial results. Related materials will be posted on the company’s investor website before the call.
Why it matters — OCGN watchers can use the scheduled update and results to learn more about the company’s business and financial performance.
Ocugen announced a licensing agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding, granting exclusive rights to OCU400 for retinitis pigmentosa in the Middle East and North Africa.
Why it matters — The agreement gives OCU400 an exclusive regional licensing arrangement in MENA, a development relevant to OCGN watchers tracking the therapy’s commercialization.
PRNewsWire invited Ocugen shareholders to contact a firm to discuss their rights and options at no cost or obligation. The firm said it would handle matters on a contingent-fee basis, with no out-of-pocket payment for its legal fees or expenses.
Why it matters — The item raises a shareholder-rights issue involving Ocugen, which may be relevant to investors following the company.
Hemostemix announced full approval from The Bahamas’ LARTA Board, including ethics approval, for a commercial Phase 1 study of VesCell™ to treat angina, vascular dementia and pain.
Why it matters — The announcement concerns Hemostemix and does not describe a development or update involving Ocugen.
The 6 Wall Street analysts covering Ocugen, Inc. have a median 12-month price target of $11, with estimates ranging from $8 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Ocugen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocugen, Inc. 24 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Ocugen, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +1252.4% from the last close, and Ticker Nerd's factor model ranks Ocugen, Inc. 24 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ocugen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $22 over the next 12 months.
Ocugen, Inc. returned -48.9% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ocugen, Inc. is a biotechnology company focused on developing gene and cell therapies, biologics, and vaccines designed to address serious and underserved medical conditions.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Ocugen to Participate in Upcoming November Investor and Industry Conferences". Ocugen announced it will present its modifier gene therapy platform at investor and industry conferences in November 2026.
Ocugen, Inc. is a biotechnology company focused on developing gene and cell therapies, biologics, and vaccines designed to address serious and underserved medical conditions. Its current work spans ophthalmology, immunology, and infectious disease, with research programs targeting inherited retinal disorders, blindness caused by retinal degeneration, and other conditions involving vision loss. The company also develops cellular therapies intended to support tissue repair and restore function, including approaches focused on cartilage and joint health. Ocugen, Inc. combines biotechnology research, clinical development, and potential commercialization activities to advance innovative treatments from laboratory concepts toward patient care. Its role in the financial market reflects the characteristics of a specialized biopharmaceutical business, where value is linked to scientific platforms, therapeutic development programs, regulatory progress, and the potential medical applications of its pipeline. The company serves the broader healthcare and life sciences sectors through its focus on novel treatments and vaccine technologies.
CEO Dr. Shankar Musunuri M.B.A., Ph.D. · 116 employees · United States · https://www.ocugen.com
